Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$7.4 million.

  • Lyra Therapeutics' Free Cash Flow rose 5447.95% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.1 million, marking a year-over-year increase of 5780.72%. This contributed to the annual value of -$72.3 million for FY2024, which is 1242.87% down from last year.
  • According to the latest figures from Q3 2025, Lyra Therapeutics' Free Cash Flow is -$7.4 million, which was up 5447.95% from -$6.6 million recorded in Q2 2025.
  • Over the past 5 years, Lyra Therapeutics' Free Cash Flow peaked at $2.8 million during Q2 2021, and registered a low of -$24.6 million during Q1 2024.
  • Its 5-year average for Free Cash Flow is -$12.2 million, with a median of -$12.0 million in 2022.
  • Per our database at Business Quant, Lyra Therapeutics' Free Cash Flow crashed by 40783.74% in 2022 and then soared by 6733.9% in 2025.
  • Over the past 5 years, Lyra Therapeutics' Free Cash Flow (Quarter) stood at -$12.4 million in 2021, then increased by 1.52% to -$12.2 million in 2022, then crashed by 62.77% to -$19.8 million in 2023, then skyrocketed by 43.09% to -$11.3 million in 2024, then skyrocketed by 34.41% to -$7.4 million in 2025.
  • Its Free Cash Flow stands at -$7.4 million for Q3 2025, versus -$6.6 million for Q2 2025 and -$8.8 million for Q1 2025.